Phaseline

Targets › ACADM

ACADM (Medium-chain specific acyl-CoA dehydrogenase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Jan 2028.

Medium-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation (FAO), breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats. The first step of FAO consists in the proR-proR stereospecific alpha, beta-dehydrogenation of fatty acyl-CoA thioesters using the electron transfer flavoprotein (ETF)…. (UniProt, P11310)

Open in Phaseline: the race on ACADM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jerry Vockley, MD, PhDSodium phenylbutyrate (ACER-001)
Nitrogen scavenger; ammonia-lowering agent that may stabilize or improve mutant ACADM prot
ACADMPhase 2Medium-chain Acyl-CoA Dehydrogenase DeficiencyJan 2028

Conditions

Medium-chain Acyl-CoA Dehydrogenase Deficiency (1)

Modalities

small molecule (1)

Companies

Jerry Vockley, MD, PhD (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.